Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis - Université de Lorraine Access content directly
Journal Articles Drug Safety Year : 2021

Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis

Abstract

Sphingosine-1-phosphate modulators are approved for the treatment of multiple sclerosis and are under development for other immune-mediated conditions; however, safety concerns have arisen.
PROSPERO CRD42020172575.

Domains

Life Sciences [q-bio]

Benjamin GROSJEAN  : Connect in order to contact the contributor

https://hal.univ-lorraine.fr/hal-04214849

Submitted on : Friday, September 22, 2023-11:54:17 AM

Last modification on : Friday, March 22, 2024-11:30:40 AM

No file

Dates and versions

hal-04214849 , version 1 (22-09-2023)

Identifiers

Cite

Juan Lasa, Pablo Olivera, Stefanos Bonovas, Silvio Danese, Laurent Peyrin-Biroulet. Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis. Drug Safety, 2021, 44 (6), pp.645-660. ⟨10.1007/s40264-021-01057-z⟩. ⟨hal-04214849⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

UNIV-LORRAINE NGERE-UL BMS-UL
3 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More